What were the main drivers of revenue growth in the first quarter of 2008?

Revenue growth was primarily driven by a 20% increase in net sales to $5.2 billion. Pharmaceutical net sales saw a significant rise of 21% to $4.2 billion, fueled by strong performance from key products such as PLAVIX® (up 39%) and ABILIFY® (up 24%). Favorable foreign exchange impacts also contributed positively to the overall sales increase.

What is the status of the PLAVIX® patent litigation?

The company is actively involved in patent litigation concerning PLAVIX®. In the U.S., a district court upheld the validity of a key patent until November 2011 and enjoined Apotex from marketing its generic product. Apotex's appeal is pending. Internationally, there are ongoing legal proceedings in Canada, Korea, and Australia related to PLAVIX® patents. The company notes that the loss of market exclusivity for PLAVIX® would be material to its results.

How is the company addressing costs and operational efficiency?

Bristol-Myers Squibb is executing a multi-year strategy focused on transforming into a next-generation biopharmaceutical company. A key component is the Productivity Transformation Initiative (PTI), which aims to achieve $1.5 billion in annual cost savings and cost avoidance by 2010. In the first quarter of 2008, the company incurred $113 million in charges related to the PTI, which includes downsizing and streamlining operations.

What was the impact of the sale of the Medical Imaging business?

In January 2008, the company completed the sale of its Medical Imaging business to Avista Capital Partners L.P. for approximately $525 million. This transaction resulted in a pre-tax gain of $25 million and an after-tax loss of $43 million, which are reported within discontinued operations. The proceeds from this sale contribute to the company's financial flexibility.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q1 FY2008

Summary

Bristol-Myers Squibb Company (BMY) reported a strong first quarter for 2008, with net sales increasing by 20% to $5.2 billion, primarily driven by a significant surge in pharmaceutical net sales, which grew 21% to $4.2 billion. This growth was bolstered by key products like PLAVIX® and ABILIFY®, alongside favorable foreign exchange impacts and the residual effects of generic competition in the prior year. Earnings from continuing operations also saw a healthy increase of 9% to $701 million, leading to basic and diluted earnings per share of $0.35. The company continues to advance its strategic transformation into a next-generation biopharmaceutical company, marked by the sale of its Medical Imaging business and progress on a strategic direction for ConvaTec. The Productivity Transformation Initiative (PTI) is on track to deliver substantial cost savings. BMY also highlighted pipeline advancements and new regulatory filings, demonstrating a commitment to future growth in specialty medicines and biologics. Despite some ongoing legal challenges, particularly concerning PLAVIX® patent litigation, the company generated robust operating cash flow and maintained a solid financial position.

Key Highlights

1Net sales increased by 20% to $5.2 billion in Q1 2008 compared to Q1 2007.
2Pharmaceutical net sales grew by 21% to $4.2 billion, driven by strong performance of key products like PLAVIX® and ABILIFY®.
3Earnings per share (EPS) from continuing operations rose to $0.35, a 9% increase year-over-year.
4The company completed the sale of its Medical Imaging business for approximately $525 million.
5Operating cash flow was strong at $779 million for the quarter.
6The Productivity Transformation Initiative (PTI) is on track to achieve $1.5 billion in annual cost savings by 2010.
7Significant pipeline developments and regulatory filings were noted, including for the diabetes medicine saxagliptin.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 2008

Summary

Key Highlights

Frequently Asked Questions